Compare ORA & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORA | RGEN |
|---|---|---|
| Founded | 1965 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.6B |
| IPO Year | 2004 | 1995 |
| Metric | ORA | RGEN |
|---|---|---|
| Price | $111.75 | $141.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $127.82 | ★ $167.67 |
| AVG Volume (30 Days) | 856.3K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | ★ 0.71 | 0.15 |
| Revenue | ★ $719,267,000.00 | $141,236,000.00 |
| Revenue This Year | $16.52 | $14.30 |
| Revenue Next Year | $3.64 | $14.52 |
| P/E Ratio | ★ $158.56 | $949.33 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $84.13 | $100.99 |
| 52 Week High | $146.39 | $175.77 |
| Indicator | ORA | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 61.53 |
| Support Level | $109.93 | $123.05 |
| Resistance Level | $114.82 | $141.46 |
| Average True Range (ATR) | 4.52 | 6.31 |
| MACD | -2.74 | 0.44 |
| Stochastic Oscillator | 16.36 | 68.45 |
Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: the Electricity Segment. where the company develops, builds, owns, and operates geothermal, solar PV, and recovered energy-based power plants in the United States and geothermal power plants in other countries and sells the electricity generated. Product Segment includes designing, manufacturing, and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement, and construction of geothermal & recovered energy-based power plants. Energy Storage Segment includes owning & operating grid-connected which provide capacity, energy, & ancillary services directly to the electric grid.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.